Punctal plug demonstrates proof of concept
QLT Plug Delivery, Inc. has demonstrated proof of concept of its punctal plug drug delivery technology, showing that it is both well tolerated and effective at lowering intraocular pressure (IOP).
QLT Plug Delivery, Inc. has demonstrated proof of concept of its punctal plug drug delivery technology, showing that it is both well tolerated and effective at lowering intraocular pressure (IOP).
QLT Plug Delivery is a wholly-owned subsidiary of QLT, Inc.
The open label study evaluated the punctal plug, which elutes latanoprost, in five patients (10 eyes) with glaucoma or ocular hypertension. Mean IOP was measured over a 90-day period. Six eyes completed the study; two patients lost plugs, but no serious adverse events were reported.
Mean IOP at baseline was 23 mmHg; 90 days after insertion of the punctal plugs, mean IOP decreased to 17 mmHg.
Patients are now being enrolled in a Phase II randomized, double-masked trial assessing the punctal plug delivery system with low, medium and high doses of latanoprost for the treatment of glaucoma and ocular hypertension.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
